Pharma Pulse 3/28/24: Do Mixed Results Impact Potential Real-World Effectiveness? FDA Issues Letters Over Unapproved, Misbranded OTC Analgesic Products & more

Do Mixed Results Impact Potential Real-World Effectiveness and Potential Market Adoption?

In this Pharmaceutical Executive video interview, Optum Rx clinical pharmacist, Arash Sadeghi, explore mixed trial results impact the confidence in their potential real-world effectiveness and potential market adoption.

FDA Issues Letters to 6 Companies for Unapproved, Misbranded OTC Analgesic Products

The agency warns consumers against using these products, which are marketed for topical use to relieve pain associated with cosmetic procedures.

The Fight for AI Talent: Pay Million-Dollar Packages and Buy Whole Teams

Search for AI expertise heats up amid a shortage of candidates and as layoffs hit other areas of tech

Indivi to Collaborate with Biogen to Advance Digital Health Technology and Digital Biomarkers for Parkinson’s Disease

Indivi, a MedTech company headquartered in Basel, Switzerland, has entered into an agreement with Biogen to advance digital health technology and develop digital biomarkers for Parkinson’s disease. As part of the agreement, Biogen will license KonectomTM to Indivi, a smartphone-based digital biomarker platform that assesses neurological functions remotely for more precise, frequent measurement of disease evolution.

Open Credentialing Initiative (OCI) on LinkedIn:

Dave DeJean from Systech International shares insights on the pharma supply chain's adherence to the Drug Supply Chain Security Act (DSCSA).Explore his perspective on the FDA's 'Stabilization Period' and proactive measures the pharmaceutical industry can implement to avoid penalties in the future.

Pharmaceutical Commerce Magazine

Listen to the podcast here:https://lnkd.in/epjAeKyi

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs